Personalis Inc
PSNL5.515USD
+0.125+2.32%
交易中 （美东）报价延迟15分钟
487.08M总市值
亏损市盈率 TTM
关于 Personalis Inc 公司
Personalis, Inc. 致力于开发和营销先进的癌症基因组测试和分析。该公司先进的基因组测序和分析支持个性化癌症疫苗和其他下一代癌症免疫疗法的开发。其产品包括 NeXT Personal、ImmunoI DNeXT、NeXT Personal Dx、NeXT Dx、全外显子组测序 (WES) 和全基因组测序 (WGS)。NeXT Personal 是一种肿瘤知情液体活检测试，用于检测癌症中的微小残留病 (MRD) 和复发。NeXT Dx 是一种全面的肿瘤分析测试，可通过匹配的肿瘤正常分析解锁整个外显子组 (DNA) 和转录组 (RNA)。该公司对人类样本进行了 WGS，用于研究项目，例如人口测序计划。该公司的测试和分析被制药公司用于转化研究、生物标志物发现、个性化癌症疗法的开发。
公司简介
公司代码PSNL
公司名称Personalis Inc
上市日期Jun 20, 2019
CEOMr. Christopher M. (Chris) Hall
员工数量229
证券类型Ordinary Share
年结日Jun 20
公司地址6600 Dumbarton Circle
城市FREMONT
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编94555
电话16507521300
网址https://www.personalis.com/
公司代码PSNL
上市日期Jun 20, 2019
CEOMr. Christopher M. (Chris) Hall
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Aaron Tachibana
Mr. Aaron Tachibana
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
163.21K
-0.39%
Dr. Richard Chen, M.D.
Dr. Richard Chen, M.D.
Executive Vice President - Research and Development, Chief Medical Officer
Executive Vice President - Research and Development, Chief Medical Officer
120.75K
-0.37%
Ms. Lonnie Shoff
Ms. Lonnie Shoff
Independent Director
Independent Director
20.63K
+99.99%
Ms. Karin Eastham, CPA
Ms. Karin Eastham, CPA
Independent Chairman of the Board
Independent Chairman of the Board
13.51K
--
Mr. Stephen Moore
Mr. Stephen Moore
Senior Vice President, Chief Legal Officer, and Corporate Secretary
Senior Vice President, Chief Legal Officer, and Corporate Secretary
--
--
Mr. Woodrow A. (Woody) Myers, Jr., M.D.
Mr. Woodrow A. (Woody) Myers, Jr., M.D.
Independent Director
Independent Director
--
--
Ms. Olivia K. Bloom, CPA
Ms. Olivia K. Bloom, CPA
Independent Director
Independent Director
--
--
Mr. A. Blaine Bowman
Mr. A. Blaine Bowman
Independent Director
Independent Director
--
--
Mr. Christopher M. (Chris) Hall
Mr. Christopher M. (Chris) Hall
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Aaron Tachibana
Mr. Aaron Tachibana
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
163.21K
-0.39%
Dr. Richard Chen, M.D.
Dr. Richard Chen, M.D.
Executive Vice President - Research and Development, Chief Medical Officer
Executive Vice President - Research and Development, Chief Medical Officer
120.75K
-0.37%
Ms. Lonnie Shoff
Ms. Lonnie Shoff
Independent Director
Independent Director
20.63K
+99.99%
Ms. Karin Eastham, CPA
Ms. Karin Eastham, CPA
Independent Chairman of the Board
Independent Chairman of the Board
13.51K
--
Mr. Stephen Moore
Mr. Stephen Moore
Senior Vice President, Chief Legal Officer, and Corporate Secretary
Senior Vice President, Chief Legal Officer, and Corporate Secretary
--
--
Mr. Woodrow A. (Woody) Myers, Jr., M.D.
Mr. Woodrow A. (Woody) Myers, Jr., M.D.
Independent Director
Independent Director
--
--
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
United States
18.13M
88.00%
Others
2.47M
12.00%
业务
地区
暂无数据
股东统计
更新时间: 7月26日 周六
更新时间: 7月26日 周六
持股股东
股东类型
持股股东
持股股东
占比
Merck & Co Inc
15.90%
Tempus AI Inc
14.40%
Lightspeed Venture Partners
9.24%
ARK Investment Management LLC
8.05%
AIGH Capital Management, LLC.
3.15%
Other
49.26%
持股股东
持股股东
占比
Merck & Co Inc
15.90%
Tempus AI Inc
14.40%
Lightspeed Venture Partners
9.24%
ARK Investment Management LLC
8.05%
AIGH Capital Management, LLC.
3.15%
Other
49.26%
股东类型
持股股东
占比
Corporation
30.30%
Investment Advisor
17.42%
Investment Advisor/Hedge Fund
10.89%
Venture Capital
9.33%
Hedge Fund
3.49%
Private Equity
3.15%
Research Firm
1.79%
Individual Investor
1.18%
Pension Fund
0.67%
Other
21.77%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
223
69.16M
78.30%
+787.53K
2025Q1
223
76.78M
86.93%
+10.49M
2024Q4
213
73.54M
83.34%
+21.51M
2024Q3
203
51.51M
73.15%
+1.63M
2024Q2
208
30.80M
57.54%
-8.76M
2024Q1
264
31.11M
59.99%
-9.40M
2023Q4
271
31.05M
62.33%
-8.25M
2023Q3
297
34.10M
70.92%
-7.87M
2023Q2
312
35.53M
73.99%
-8.07M
2023Q1
327
36.62M
78.29%
-6.81M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Merck & Co Inc
14.04M
15.9%
--
--
Mar 31, 2025
Tempus AI Inc
12.72M
14.4%
+3.50M
+37.97%
Aug 16, 2024
Lightspeed Venture Partners
8.16M
9.24%
--
--
Mar 31, 2025
ARK Investment Management LLC
7.19M
8.14%
+412.76K
+6.09%
Mar 31, 2025
AIGH Capital Management, LLC.
2.98M
3.37%
+176.67K
+6.30%
Mar 31, 2025
abrdn Inc.
1.70M
1.93%
+1.41M
+472.29%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.70M
1.92%
+6.34K
+0.37%
Mar 31, 2025
The Vanguard Group, Inc.
1.29M
1.46%
-444.30K
-25.61%
Mar 31, 2025
Blue Water Life Science Advisors, LP.
1.18M
1.33%
+42.50K
+3.75%
Mar 31, 2025
BlackRock Financial Management, Inc.
1.08M
1.22%
-20.66K
-1.87%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
ARK Genomic Revolution ETF
4.48%
Invesco NASDAQ Future Gen 200 ETF
0.64%
Global X Genomics & Biotechnology ETF
0.52%
iShares Micro-Cap ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
iShares Biotechnology ETF
0.04%
Avantis US Small Cap Equity ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
查看更多
ARK Genomic Revolution ETF
占比4.48%
Invesco NASDAQ Future Gen 200 ETF
占比0.64%
Global X Genomics & Biotechnology ETF
占比0.52%
iShares Micro-Cap ETF
占比0.07%
ProShares Ultra Nasdaq Biotechnology
占比0.06%
Invesco Nasdaq Biotechnology ETF
占比0.06%
iShares Biotechnology ETF
占比0.04%
Avantis US Small Cap Equity ETF
占比0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0.03%
iShares Russell 2000 Value ETF
占比0.02%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
